The clinical efficacy of MR antagonists after MI (Pitt et al. 2003) and in heart failure (Pitt et al. 1999, Zannad et al. 2011, 2012) are attributed, at least in part, to blockade of MR activation in the heart. This evidence concerns the gene NR3C2 and myocardial infarction.